. Thus conservative management strategies are essential for decreasing the downstream harms of screening by reducing overtreatment of men with low-risk disease 6 . Two main strategies of conservative management are watchful waiting and active surveillance (AS). Watchful waiting is not pursued with curative intent, but rather this option aims to manage symptoms for men with clinical progression. AS, on the other hand, aims to delay or avoid treatment of favourable-risk cancers in men who are candidates for active treatment. Under this approach, treatment with curative intent is recommended upon evidence of reclassification to higher-risk disease. First reported in 2002 (REFS 7, 8) , AS programmes vary in both protocol and practice. This Review will discuss the contemporary literature regarding utilization, selection, monitoring, and outcomes associated with AS worldwide.
Utilization of active surveillance
Until the past 5 years, the use of conservative management for low-risk prostate cancer remained limited in the US and many other countries. Several studies on management trends have been published using data from the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry, which encompasses 45 urology practices across the USA 9, 10 . In 2000-2001, only 6.2% of men with low-risk prostate cancer were managed by AS or watchful waiting, increasing slightly to 10.2% in 2004 10.2% in -2006 ). However, the use of AS or watchful waiting has accelerated in the USA -according to the most recent data from 2010 to 2013, 40.4% of lowrisk tumours were managed by AS or watchful waiting, and this rate was even higher in men aged ≥75 years, at 76.2% 10, 11 
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prostate cancer more than doubled, increasing from 17% to 42%. Expectant management was also selected by 13% of patients with intermediate-risk disease, with no significant change over time. Additional data on treatment trends were reported by Womble et al. 13 who analysed data from the Michigan Urologic Surgery Improvement Collaborative (MUSIC), which includes 42 urology practices in Michigan. Among 627 men in the MUSIC registry diagnosed with low-risk prostate cancer from 2012 to 2013, 49% underwent AS. Notably, the adjusted AS utilization rates did vary widely among practices, from 27 to 80%, a finding which has also been reported in other clinical practice settings such as the US veterans health 14 . The use of AS has also increased globally. In Sweden, data from the National Prostate Cancer Register demonstrated an increase in the use of deferred treatment over time 15 . Between 2007 and 2011, 59% of men with verylow-risk, 41% with low-risk, and 16% with intermediaterisk prostate cancer were managed using AS. Use of AS has similarly expanded in Australia 16 . Using data from the Victorian Prostate Cancer Registry collected from 2008 to 2012, Weerakoon et al. 16 reported a sharp increase in use of AS during the second half of 2010, including 39.7% of very-low-risk and low-risk cases, a rate that was maintained thereafter. Interestingly, the authors reported significantly greater utilization of AS for men with very-low-risk and low-risk disease in the private versus public sector (38.3% versus 31.6%, P = 0.005). However, overall trends toward increasing use of AS are not universal -in a 2014 nationwide survey of 2,133 Japanese urologists, 26.9% reported no use of AS for localized prostate cancer, and another 50.6% reported using AS in <5% of patients 17 . Moreover, only 27.0% of respondents indicated that they want to use AS more frequently in the future.
The increased use of AS in many countries has been accompanied by a corresponding decrease in the proportion of men undergoing radical prostatectomy for low-risk disease. In Canada, Louis et al. 18 reported a steady decline in the proportion of radical prostatectomies performed for low-risk disease. Similarly, data from the Martini Clinic in Germany demonstrated that by 2014 only 12.1% of men had solely Gleason score 6 prostate cancer in the radical prostatectomy specimen, compared with 52.2% in 2000 (REF. 19 ). These combined data suggest a global trend towards an expanding use of conservative management and a reduction in overtreatment of low-risk disease.
Patient selection
Nine major international AS programs met our inclusion criteria and described guidelines for patient selection [20] [21] [22] [23] [24] [25] [26] [27] [28] (TABLE 1) . Eight of the nine programmes outline specific criteria for inclusion in AS, whereas the Göteborg cohort allowed for consideration of AS for men with screen-detected cancers at the discretion of the physician and patient 24 . Godtman and colleagues 22 reported that the majority of this population had favourable-risk disease (51% very-low-risk, 27% low-risk), but it is notable that 21% of patients had intermediate-risk tumours and 1% high-risk. The selection criteria of most programmes were based on the D' Amico or National Comprehensive Cancer Network (NCCN) classification of low-risk cancer (≤cT2a, PSA<10 ng/ml, Gleason score ≤6), with some slight variations on the precise definition of 'low-risk' disease.
The most stringent criteria are used in the Johns Hopkins programme 20 , where inclusion is based on the Epstein criteria for clinically insignificant prostate cancer (T1c, PSAD <0.15 ng/ml, Gleason score ≤6, ≤2 positive biopsy cores, and ≤50% involvement of any biopsy core) 29, 30 . The NCCN subsequently modified the Epstein criteria by adding PSA <10 ng/ml to establish a definition of very-low-risk disease 31 . As the Hopkins experience has indicated that a PSA threshold of 10 ng/ml might not improve selection among men with PSAD <0.15 (REFS 32, 33) , the very-low-risk disease cohort at JHU has not adopted a strict PSA threshold as has the NCCN. Notably, Reese and colleagues 34 recently evaluated the pathology at radical prostatectomy in men who met some, but not all, of the Epstein criteria and found simi lar pathology with clinical stage T2 lesions, up to three positive biopsy cores, and/or up to 60% involvement of any core with cancer. Although the JHU programme traditionally offered AS only to men with very-low-risk tumours, the programme has permitted men with low-risk prostate cancer seeking a conservative approach to participate in the AS programme.
Some programmes have also reported the outcomes of AS in patients with intermediate-risk cancer. For example, Klotz and colleagues 21 at Sunnybrook have offered AS to some men with intermediate-risk features such as GS ≤3 + 4 and/or PSA 10-20 ng/ml with a life expectancy of less than 10 years. The Royal Marsden program includes men with GS ≤3 + 4 disease if less than 50% of biopsy cores are positive, PSA is less than 15 ng/ml, and the patient is older than 65 years 24 . Although not formally meeting inclusion criteria, a number of other cohorts have monitored men with
Key points
• The nature of a given active surveillance (AS) protocol is dependent on the three core components of AS: criteria for selection, monitoring strategy, and triggers for intervention • Among large AS programmes, selection criteria range from very-low-risk to intermediate-risk disease, and monitoring protocols vary widely in frequency of prostate biopsy; histological upgrading is a trigger for intervention in most programmes • In AS cohorts with at least 5 years of available follow-up data, treatment was pursued in 24-40% of men; metastatic disease occurred in 0.1-2.8%, and prostate-cancer-specific death in 0-1.5% • Intermediate-term outcomes are dependent on programme-specific criteria;
intensive programmes (close monitoring, low intervention thresholds) are associated with high rates of treatment and low rates of adverse oncological outcomes • In the absence of a single optimal AS protocol, individualizing AS intensiveness to each man's risks and expectations is a reasonable approach, only once he has been counselled on the existing data and its known limitations • Accurate measurement and reporting of time-dependent data are critical in order to establish reliable benchmarks for counselling and pave the way toward identifying an optimized approach 25 .
Monitoring and triggers for intervention
Clinical examination, serum PSA levels, and transrectal ultrasonography (TRUS)-guided biopsy have traditionally formed the basis of initial monitoring protocols 7, 8 , and the majority of programmes continue to use these assessments. All the major AS programmes include PSA testing, ranging from 3-6 monthly throughout the course of surveillance [20] [21] [22] [23] [24] [25] [26] [27] [28] . However, variation exists in the timing and frequency of biopsies obtained. Seven of nine programmes include mandatory rebiopsy for all patients within the first 12-15 months after enrolment, whereas the programme at the Royal Marsden performs rebiopsy within 18-24 months 24 , and the Göteborg group recommends early rebiopsy only in men with <2 mm cancer on their diagnostic biopsy 22 . Frequency of subsequent repeat biopsies, however, varies across cohorts from 1 year to up to 4 years, in the absence of other concerning findings (TABLE 2) .
Greater variation exists among clinical and pathological findings that prompt intervention. Pathological upgrading from Gleason 6 to any Gleason 7 triggers intervention in seven programmes, whereas two others recommend intervention only when primary Gleason pattern 4 is demonstrated 24, 27 . Increased volume of cancer, or volume reclassification -as assessed by the number or proportion of positive biopsy cores and the maximum involvement of any one core -is also a trigger for intervention in seven programmes. Four programmes currently have PSA kinetic thresholds for intervention -either PSA doub ling time (PSADT) <3 or PSA velocity (PSAV) >0.75-1.0. Although not a formal trigger for intervention, the literature demonstrates that a proportion of men elect to undergo treatment for other reasons, such as a change in preference. Furthermore, a number of traditional and emerging markers have been explored for utility in monitoring patients on AS, and for triggering active intervention.
PSA kinetics
As serial PSA measurements are obtained in virtually all AS programmes, PSA kinetic measurements such as PSAV and PSADT have been extensively evaluated as predictors of progression 35 . In many AS programmes, PSA kinetics were historically used as a trigger for intervention, and, based on circular reasoning, there has been a strong association between PSA kinetics and progression to treatment 36, 37 . However, studies have shown that PSA kinetics are not a reliable predictor of biopsy reclassification during AS 38,39 -although a trend toward higher PSAV among those with biopsy reclassi fication was observed in the Johns Hopkins AS programme, there was no significant difference in PSADT between biopsy progressors and non-progressors (3.1 years versus 2.5 years, P = 0.83) 38 . Furthermore, it was not possible to identify a clinically useful cut-off point for either variable with good performance charac teristics. As a result, most major AS programmes now consider PSA kinetics as a trigger for further diagnostic evaluation rather than as a trigger for intervention 40 (TABLE 2) . However, men whose disease has been stable on AS for several years, can also benefit from the use of PSA kinetics 41 ; Patel et al. 42 showed that men with multiple successive PSAV measurements >0.4 ng/ml/year have a greater risk of biopsy reclassification beyond the first 2 years of AS.
Other PSA-based measurements Other variations on PSA measurement can be used to predict progression during AS, such as PSA density (PSAD). Several studies have shown that PSAD at the time of diagnostic biopsy, and also at subsequent surveillance biopsies, is predictive of biopsy reclassification 43 . Nonetheless, at the time of writing, PSAD has not been cited as a formal trigger for intervention in the literature. The Prostate Health Index (phi) is another adjunctive PSA-based measurement combining total, free, and [-2]proPSA using a mathematical formula. The use of phi was approved by the FDA in 2012 as an aid in early prostate cancer detection 44 , and in that context has been shown to outperform PSA and free PSA for identifying 
Volume reclassification
Increase in risk categorization based on increased volume of cancer on prostate biopsy. As very-low-risk cancer is the only risk category based on cancervolume-specific criteria, volume reclassification occurs only in men harbouring very-low-risk disease.
clinically significant prostate cancer 45 . Among men on AS, both baseline and longitudinal values of phi are predictors of biopsy reclassification 46, 47 . Additional studies are needed to identify how phi can be best utilized, possibly in conjunction with imaging, to help monitor men during AS.
Urinary markers
Urinar y markers, most notably PCA3 and TMPRSS2:ERG fusions, have also been examined for utility in monitoring during AS [48] [49] [50] . In the Canary Prostate Active Surveillance Study, both of these markers were associated with high-grade (Gleason score ≥7) disease on univariable analysis (median PCA3 scores: 27 for no cancer, 31 for Gleason score ≤6, 48 for Gleason score ≥7, P = 0.02; median TMPRSS2:ERG scores: 5 for no cancer, 14 for Gleason score ≤6, 29 for Gleason score ≥7, P = 0.001) but addition of these markers did not significantly improve upon PSA alone in predicting high-grade disease (AUC 0.68 versus 0.70, P = 0.08) 48 . Similarly, in the Johns Hopkins programme, PCA3 was not a reliable predictor of reclassification on surveillance biopsy (AUC 0.589) 49 . Finally, Cornu et al. 50 examined PCA3 and TMPRSS2:ERG in a mixed population of men undergoing prostate biopsy triggered by a serum PSA measurement >3 ng/ml and men having restaging biopsy to assess candidacy for AS. In the combined cohort, neither PCA3 nor TMPRSS2:ERG were significantly associated with Gleason pattern 4 disease on biopsy on univariate analysis. However, PCA3 (normalized coefficient 0.291, P = 0.029) was a significant predictor of Gleason pattern 4 in the multivariable model and a trend toward significance with increasing TMPRSS2:ERG (normalized coefficient 0.032, P = 0.052) was also observed. Overall, insufficient data currently exist to demonstrate the utility of urinary markers in patients on AS programmes, but further research is warranted to determine whether a combination panel of these noninvasive tests could potentially have a role in certain patient subgroups in the future.
Genomic tests
Several commercially-available genomic tissue tests could have potential applications in the selection of candidates for AS. Prolaris® (Myriad Genetics, Salt Lake City Utah, USA) is one such test that measures cellcycle-progression genes to create a cell cycle progression (CCP) score. In a group of men diagnosed with prostate cancer in 1990-1996 who were managed conservatively, CCP measured in archived tissue from the diagnostic biopsy predicted the risk of prostate-cancer-associated death 51 . Further studies have shown that CCP scores from the diagnostic biopsy predict the risk of adverse pathology at radical prostatectomy, and biochemical progression following prostatectomy and radiation therapy 52, 53 . Despite growing data suggesting that baseline CCP score can help with risk stratification and influence treatment recommendations 54 , no data exist regarding the usefulness of serial CCP testing during AS.
OncotypeDx® (Genomic Health, Inc. Redwood City, California, USA) measures genes from four different pathways associated with prostate cancer to calculate a genomic prostate score (GPS), which might be useful in risk stratification. GPS measured on diagnostic biopsy samples independently predicts the risk of adverse pathology among patients with low-to-intermediate-risk Criteria prior to 2000: Gleason score ≤6 and serum PSA ≤10 ng/ml, or Gleason score ≤3 + 4, serum PSA ≤15 ng/ml, age >70 years. § AS was elected based on patient and physician discretion. Entry was based upon "presumed low-risk prostate cancer," but men with higher risk disease could participate based on patient preference or comorbidity.
disease undergoing radical prostatectomy 55, 56 , and it can, therefore, also be used in the context of initial treatment decisions. Similarly, the ProMark® test (Metamark, Cambridge, Massachusetts, USA) aims to predict cancer aggressiveness based on an eight-protein signature. In 276 men with matched biopsy and prostatectomy specimens, ProMark® was sensitive and specific for predicting unfavourable pathology in approximately 40% of the cohort 57 . No data on serial use of these markers in AS protocols have been reported.
Multiparametric MRI
Multiparametric MRI (mpMRI) has emerged as a useful adjunct tool in the detection of prostate cancer, and several studies have shown that suspicious findings on MRI predict an increased risk of reclassification during AS [58] [59] [60] [61] [62] [63] . Two of the large prospective AS programmes have reported their indications for use of mpMRI. In the Sunnybrook cohort, Klotz et al. 21 report that mpMRI is currently used in men indicated for closer scrutiny, such as those with adverse PSA kinetics. At the Royal Marsden, although mpMRI was not initially a routine part of their protocol, the protocol has since been amended to include baseline and surveillance mpMRI for all men on AS 24 . However, uniform methods for incorporating mpMRI into surveillance protocols have not yet been described and, as the role of serial mpMRI during AS is not yet clearly defined, contemporary surveillance programmes continue to rely on repeat prostate biopsy. Although we await additional long-term data on the performance of mpMRI during AS, it has demonstrated great potential in both the identification of higher-grade cancers and in targeting specific lesions during prostate biopsy [63] [64] [65] [66] . Given the importance of these capabilities in the AS setting, mpMRI is likely to become a larger component of AS programmes in the future, and new criteria might need to be defined to characterize clinically significant disease based on targeted biopsy.
Outcomes
General demographic and follow-up characteristics of published AS cohorts vary widely (TABLE 3) . The nine reports include a total of 7,552 men with a median age of 63-68 years. Median follow-up duration ranged from 1.6 to 6.4 years, with five programmes demonstrating at least 5 years median follow-up period [20] [21] [22] [23] [24] . As some programmes included men with intermediate-risk cancers, and cancer grade is the strongest predictor of long-term cancer-specific outcomes 67 , the proportion of each cohort containing Gleason score≥7 cancers is noted and ranges from 0-14%. The overall proportion of men treated during the follow-up period ranged from 14-38%.
Additional data were obtained from cohorts with ≥5 years follow-up duration [20] [21] [22] [23] [24] (TABLE 4) . Notably, time-adjusted outcomes were seldom reported, but are provided in all such cases. In other cases, the overall proportion experiencing the outcome is provided; these measures are dependent on follow-up time and are, therefore, not well suited for comparison. These values should be interpreted with caution in the context of the median follow-up time provided.
At 5 years follow-up duration, the proportion of men treated ranged from 24-40%. Among three cohorts reporting the crude proportion of treated men that experienced biochemical recurrence (BCR), BCR ranged from 8-25% [20] [21] [22] [23] [24] . Additionally, Welty et al. 23 reported 3% BCR at the 1-year follow-up point, and Selvadurai et al. 24 reported BCR rates of 7% and 15% at 2 years and 5 years, respectively. The proportion of men who developed meta static disease (0.1-2.8%) and prostate-cancer-specific mortality (PCSM, 0-1.5%) were low according to available follow-up data. Two cohorts presented longer-term measures of PCSM 20, 21 (TABLE 4) .
Several factors are associated with biopsy reclassification or intervention in the major AS programmes 35 (TABLE 5). Of six studies reporting multivariable models, PSA density is a significant predictor of reclassification and/or intervention in four 20, 23, 25, 26 , and log-based PSA is predictive in a fifth study 21 . Age was a significant factor in three studies and PSA kinetics in two. In both studies that allowed inclusion of intermediate-risk cancers, higher biopsy Gleason score was associated with increased risk of reclassification and/or intervention 21, 24 . Among other biopsy characteristics, the volume of cancer observed on biopsy (that is, increased number and/or proportion of positive biopsy cores, increased maximum percentage involvement of any core) predicted this outcome in four such studies 20, 24, 26 .
AS in specific patient subgroups Men with intermediate-risk disease
In light of the very low incidence of adverse outcomes observed in surveillance series, an important question is whether AS can be expanded to include men with higher-risk tumours. Only two studies include selection criteria for men with intermediate-risk disease on AS, but six of the nine programmes report inclusion of some men with intermediate or high-risk disease. Outcomes were provided in four such reports 21 21 , whose study included 132 (13%) men with Gleason 7 cancer and 21% with either Gleason 7 or PSA >10 ng/ml at enrolment. The authors observed that, although 13% of the overall cohort had Gleason score 7 disease, 44% of men with metastasis came from the Gleason 7 population. At the same time, PSA (log-based) value predicted biochemical failure after treatment on multi variable analysis, whereas Gleason score did not, although this finding was likely limited by study power. These findings were consistent with those of Godtman and colleagues 22 , in which 92 (21%) of 439 men met intermediate-risk criteria. In this study, the authors defined failure as PSA recurrence after radical prostatectomy or radiation therapy, radical prostatectomy with salvage radiation, initi ation of androgendeprivation therapy (ADT), diagnosis of metastatic disease, or death from prostate cancer. On multivariable analysis, they observed a hazard ratio of 3.6 (P = 0.002) for failure in men with intermediate-risk compared with very-low risk-disease.
In Selvadurai and co-workers study 24 , 33 (7%) of 471 men had Gleason 3 + 4 = 7 cancer at enrolment. On multivariable analysis, Gleason score 7 cancer was associated with a 3.4-fold increased hazard (P = 0.005) of adverse histology, defined as Gleason score ≥4 + 3 or percentage of positive cores (PPC) >50% on follow-up biopsy, compared with the same outcomes in men with Gleason 6 disease. By contrast, Thompson and colleagues 25 found that NCCN classification was not associated with clinically significant cancer or unfavourable-risk disease at radical prostatectomy. Finally, Cooperberg and colleagues at UCSF observed .
Younger men
Enrolment in an AS programme implies a life expectancy >10-15 years; however, limited data exist exploring AS outcomes beyond 20 years. Currently, the majority of younger men diagnosed with prostate cancer undergo curative intervention 69 . However, whether AS should be considered in younger men is a particularly pertinent question 70 , as the median age at prostate cancer diagnosis continues to decrease, currently standing at 66 years 71, 72 . The majority of studies note that AS is generally recommended for older men, but explicit age criteria are rarely provided. However, some programmes use more stringent inclusion criteria for younger men. For example, Selvadurai and colleagues 24 restrict enrolment of men with intermediate-risk disease to those older than 65 years, whereas men with low-risk disease might be as young as 50 years. Similarly, Thompson and colleagues 25 consider age <55 years a high-risk feature that merits additional consideration at enrolment. Of the nine programmes considered in this Review, three studies included at least one subject in his early 40s 20, 21, 28 , and three others included men as young as 51 years 22, 24, 27 . Older age has been associated with adverse outcomes on AS, such as biopsy reclassification 20, 23, 26 . However, no studies to date have reported inferior outcomes in younger men choosing AS. Furthermore, men under 60 years' experience a greater reduction in quality of life after treatment than older men 73 . Still, in the absence of evidence, there remains concern that younger men with a long life expectancy might have more to lose by forgoing immediate cure. Reluctance to include younger men in AS programmes likely stems from the limited data on outcomes beyond 20 years.
African-American men
Contemporary AS cohorts have been limited by a lack of racial diversity. African-American men represented only 7.4% of the Johns Hopkins cohort, and just 13% of the population at the University of California San Francisco was reported as "non-white" (REFS 20, 23) . Given concerns that African-American race is associ ated with aggressive cancers 74 , many specialists have questioned whether African-American men are appropriate candidates for AS [75] [76] [77] [78] [79] . Primary manuscripts have not described race-specific outcomesmost likely owing to limited sample sizes -but several complementary studies have examined the role of race among surveillance-eligible patients.
In 2012, Iremashvili and colleagues 80 assessed progression (defined as no longer meeting AS inclusion criteria -that is, Gleason score <7, ≤2 positive cores, ≤20% cancer in any core, clinical stage ≤T2a) among AS patients at the University of Miami. On multivariable analysis, African-American race was associated with 3.79-fold greater hazard for progression (P <0.001). The authors note that the study is limited by inclusion of only 24 (9.6%) African-American men, but the findings are, nonetheless, noteworthy. Abern et al. 81 assessed 145 men including 32 (22%) African-American men for discontinuation of AS during follow-up monitoring at Duke University. The authors observed increased likelihood of treatment among African-American men (HR 2.93, P = 0.01), a finding that persisted after adjustment for clinical and socioeconomic factors (HR 3.08, P = 0.01). Similar findings were observed in a multi-institutional comparison of 67 African-American and 72 nonAfrican-American men, in which Odom and colleagues 75 observed increased risk for disease progression in the African-American group (HR 3.85, P = 0.03) after adjustment for age.
Further evidence that African-American men are subject to higher risk than similarly-staged white men has been presented by Sundi and colleagues 78 at Johns Hopkins. Among 1,801 men with very-low-risk disease (n = 256 African-American men, 14%), AfricanAmerican race was independently associated with adverse pathological features (OR 3.23, P = 0.03) and pathological upgrading (OR 2.26, P = 0.03) on multivariable analysis. Furthermore, African-American men exhibit frequent anterior and transition zone tumours, which are difficult to sample using standard biopsy techniques 82, 83 . More representative sampling could possibly be achieved using technologies such as MRI-guided fusion biopsy 66 . Regardless, Schreiber and colleagues 84 did not observe a statistically significant increase in rates of adverse pathology among African-American men 
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Nature Reviews | Urology (OR 1.43, P = 0.16) using the Surveillance, Epidemiology, and End Results programme SEER cohort, and it is possible that race-specific data are still too preliminary to trigger changes in practice 76 . Ultimately, AS might prove to be a reasonable option for some African-American men, but current AS criteria seem to perform poorly in the African-American population 85 Thus, AfricanAmerican men considering AS should be appropriately counselled regarding a potentially increased risk of adverse outcomes 79 .
Current state of AS
The prolonged natural history and disparate bio logical nature of prostate cancer necessitates a nuanced approach to management 86 . Accordingly, management strategies cover a broad spectrum, from most aggressive (that is, immediate curative intervention) to least aggressive (watchful waiting, in which treatment is offered only once symptoms arise) (FIG. 2 ). An aggressive approach confers a low risk of developing advanced, metastatic, or lethal disease, but a high risk that treatment -and its associated adverse effects -could prove unnecessary. Conversely, a conservative approach such as watchful waiting imparts minimal treatment-related adverse effects, the trade-off being an increased risk of progression to advanced disease. Certainly, men with high-risk prostate cancer and a long life expectancy are likely to benefit from an aggressive approach, just as elderly patients with indolent cancer and multiple comorbidities are less likely to benefit. Practically speaking, the vast majority of cancers cannot be easily categorized as simply aggressive versus indolent, or threatening versus nonthreatening 87 . Such limitations are further compounded by a lack of reliable methods for estimating life expectancy, a crucial consideration in the ageing population 88, 89 . AS has emerged as one strategy to help bridge the gap between these extremes of management options. In men with favourable-risk disease, in whom the benefit of treatment might be unclear, treatment is deferred in favour of a monitoring protocol to examine disease characteristics over time. In the same way that risks and benefits of management vary across the spectrum of available options, the risks and benefits of AS vary based on the nature of a given surveillance protocol. Indeed, the intensive or nonintensive nature of an AS protocol is dependent on the nature of its three core components -selection, monitoring, and intervention. AS programmes with stringent selection criteria, close monitoring, and a low threshold for intervention (intensive programs) minimize the risk of cancer progression at the expense of more frequent overtreatment. On the contrary, programmes with relaxed entry criteria, less intensive monitoring, and a high threshold for intervention (nonintensive programmes) assume a higher risk of cancer progression while limiting overtreatment.
As previously described, the Johns Hopkins (JHU) and Sunnybrook cohorts provide helpful benchmarks in determining the relative risk of various approaches to AS 20, 21 . The JHU programme is highly selective (71% participants with very-low-risk disease, 29% with low-risk disease) and involves close monitoring, with most men undergoing yearly biopsy. The Sunnybrook cohort uses less stringent selection criteria (21% participants with intermediate-risk disease, including 13% with Gleason score 7) and in most cases defers biopsy to every 3-4 years after initial rebiopsy. As could be expected, the JHU cohort demonstrated higher rates of treatment within 10 years (50% versus 36% at Sunnybrook) but lower risk of prostate cancer death (0.1% versus 1.9%). Owing to the limi tations of the published data, it must be noted that these outcomes are conveyed as overall proportions (which are dependent on follow-up duration) rather than as time-adjusted values. Median follow-up periods were 5.0 years, 6.0 years, and 6.4 years in the JHU, Göteborg, and Sunnybrook cohorts, respectively. Thus, available data support the logical hypothesis that an intensive AS approach is associated with increased rates of treatment and reduced rates of adverse oncological outcomes, and that the tradeoff in attempting to balance unnecessary treatment with the potential for adverse outcomes could have been prevented with a more aggressive approach.
Results from the Göteborg programme provide an interesting comparison 22 . The Göteborg cohort parallels Sunnybrook in the inclusion of a substantial portion of intermediate-risk patients; however, reported outcomes are in line with those observed at JHU, with rates of meta static disease of 0.4%, 0.5%, and 2.8%, and prostatecancer-specific-mortality 0.15%, 0.2%, and 1.5% at JHU, Göteborg, and Sunnybrook, respectively (taking into account the previously noted limitations of the published data). These findings are most likely explained by more frequent treatment at Göteborg compared with the Sunnybrook cohort (36%, 37%, and 27% at JHU, Göteborg, and Sunnybrook, respectively) and more frequent overall mortality compared with JHU (4%, 14%, and 15%, at JHU, Göteborg, and Sunnybrook, respectively). Outcomes from these programmes help illustrate the reality that the outcomes of AS reflect a complex interaction of cancer risk, surveillance approach, and overall patient health.
Acknowledging the shortcomings of cross-study comparisons, these data support the suggestion that men with intermediate-risk cancer are, in general, at higher risk of adverse outcomes on AS 90 . In a multi-institutional pathological analysis, Ploussard et al. 91 identified a Figure 2 | Prostate cancer is heterogeneous in nature, with a spectrum of disease ranging from indolent to highly lethal. Accordingly, options for management range from conservative approaches such as watchful waiting, to a more aggressive approach with immediate definitive treatment. Active surveillance is an accepted management strategy for favourable-risk cancers. Approaches to active surveillance vary from non-intensive in men with indolent-appearing cancers who wish to minimize the morbidity of monitoring and potential treatment to a more intensive approach in others who wish to minimize the risk of unfavourable-risk cancer remaining undetected. [92] [93] [94] . Whether this observation will translate to inferior long-term oncological outcomes remains unknown.
Early rebiopsy within 1 year of diagnosis has been adopted as one component of monitoring in most programmes, and evidence available to date strongly supports this practice. At JHU, more than half of biopsy reclassifications occurred within the first 2 years of enrolment 20 . Median times to treatment ranging from 1.2 to 2.6 years indicate similar findings at other centres 23, 26, 28 , and additional studies have demonstrated decreasing risk of progression over time 94, 95 . As other studies have noted 96 , early reclassification is more likely the result of increased sampling rather than true disease progression in the vast majority of cases. Although studies of saturation biopsy before beginning AS have produced mixed results, standard rebiopsy within the first year after enrolment has proven to be of high yield in identifying unfavourable disease and should be performed in most cases 25, [97] [98] [99] [100] . The use of PSA kinetics criteria as triggers for intervention varies across cohorts, and its value remains unproven 38, 41 . One study estimated the effect of using the PRIAS protocol -which includes less frequent biopsy and monitoring with PSADT -in men initially followed with annual biopsy on the JHU protocol 101 . The PRIAS and JHU protocols resulted in treatment at a similar time point in the majority of men; however, the PRIAS criteria led to delayed treatment in 16%, and identified progression earlier than the JHU annual biopsy in 11% -that is, the use of JHU criteria delayed treatment. Use of PSA kinetics in men enrolled on the JHU programme as is specified in PRIAS also triggered treatment in another 12% who had not demonstrated biopsy reclassification at the time of analysis. Thus, potential risks and benefits are associated with the use of PSA kinetics to trigger intervention. At present, as suggested by Klotz and colleagues 21 , the best use of PSA kinetics might be for identifying men who should undergo mpMRI or early rebiopsy, rather than as a trigger for obligatory treatment. Nonetheless, advances in imaging and molecular techniques offer the possibility that frequent rebiopsy during AS will prove unnecessary in the near future.
Future directions
Coinciding with increased acceptance of AS has been the evolution of its initial foundation. Whereas selection criteria have been traditionally based upon a single 12-core TRUS-guided biopsy, mpMRI is increasingly used as a means of lesion identification and targeting. Several institutions have reported preliminary findings based on the use of mpMRI, but the optimal approach for incorporating this emerging technology remains unclear. Furthermore, mpMRI is just one of several new technologies being studied for prostate cancer detection and risk stratification. Certainly, the introduction of new technologies has the potential to further complicate the reporting of institutional experiences with AS.
The AS literature remains limited by the lack of uniformity in reporting. Metrics such as survival free of treatment, metastasis, and PCSM are dependent on the follow-up duration, and should, therefore, be reported as time-specific outcomes. As institutional data continue to mature, time-specific data, as well as an agreed set of standard criteria
, will provide context through which we can draw greater meaning from our universal experience. Reporting outcomes in a standardized fashion is a simple first step toward answering our most pertinent questions: whether men with intermediate-risk cancer can be safely followed on AS, what will be the role of mpMRI in selection and monitoring of AS candidates, and whether scheduled, serial biopsies are truly necessary. In the evolving landscape of favourable-risk prostate cancer, these questions represent only a few of the challenges that lie ahead.
Conclusions
In the past, the relative infancy of the AS paradigm yielded a dearth of meaningful data for use in risk assessment and patient counselling. Only now, 20 years after the initiation of early AS programmes, are a large number of men reaching 10-year and 15-year time points, at which we can begin to quantify the effect of various approaches. A uniform approach to AS is appealing, but current diagnostic and prognostic tools lack the precision needed to reliably monitor men with varying risks and preferences under a single optimal approach. Furthermore, the ability to discuss varying approaches to AS and their associated risks with a newly diagnosed patient also has value. To this end, continuing to accurately measure and report meaningful outcomes from AS programmes will prove to be essential in providing optimal care to the expanding surveillance population. 
